Tag:

pain

Health

Integrated care needed for lifelong Polyendocrine Ovarian Syndrome management

by Chief Editor
written by Chief Editor

Beyond Reproductive Years: How Polycystic Ovary Syndrome (PMOS) Is Reshaping Women’s Health in Midlife—and What’s Next

Polyendocrine Ovarian Syndrome (PMOS)—formerly known as Polycystic Ovary Syndrome (PCOS)—is no longer just a condition tied to reproductive health. As women transition through perimenopause and menopause, the long-term metabolic, hormonal, and psychological impacts of PMOS become more pronounced, yet research and treatment strategies have lagged. A groundbreaking scoping review from Florida Atlantic University (FAU) reveals critical gaps in care and points to emerging trends that could redefine how PMOS is managed across a woman’s lifespan.

— ###

The Lifelong Burden of PMOS: Why Midlife Care Is Urgently Needed

PMOS affects up to 13% of women of reproductive age, making it the most common hormonal disorder globally. Yet its influence doesn’t end with fertility—it extends into midlife, where hormonal shifts during perimenopause and menopause overlap with PMOS-related dysfunction. This dual challenge can amplify risks for:

  • Metabolic health: Up to 50–70% of women with PMOS experience insulin resistance, with a fourfold increased risk of developing type 2 diabetes.
  • Cardiovascular disease: Women with PMOS face significantly higher risks of hypertension, stroke, and premature mortality—often independent of body weight.
  • Chronic pain and mental health: Up to 80% report elevated androgen levels, while 80% are overweight or obese. Depression and anxiety rates are three to five times higher than in the general population.

Despite these risks, midlife and older women remain underrepresented in PMOS research. The FAU study highlights a stark imbalance: while lifestyle interventions like diet and exercise are well-studied for metabolic outcomes, chronic pain and mental health—critical to quality of life—have been overlooked.

— ###

What the Research Says: Diet, Exercise, and the Missing Pieces

The FAU review analyzed over 2,200 studies, narrowing to 29 rigorous investigations focused on non-pharmacological and non-surgical approaches for PMOS in adult women. Key findings:

####

1. Lifestyle Interventions: The Gold Standard (But Not Enough)

Exercise emerged as the only intervention linked to both physical and mental health improvements. Dietary changes consistently improved metabolic markers like insulin regulation and body composition. Yet, these benefits often stop short of addressing:

  • Chronic pain (only two studies explored supplements for pain, with no structured management strategies).
  • Psychological distress (supplements like vitamin D and omega-3s showed metabolic benefits but no clear impact on mental health).

Did you know? A 2023 study in Menopause found that women with PMOS who engaged in high-intensity interval training (HIIT) combined with mindfulness practices reported 30% lower perceived pain levels—yet such integrated approaches remain rare in clinical guidelines.

####

2. Complementary Therapies: Promise but Inconsistency

Supplements like probiotics, herbal remedies, and plant-based extracts were widely studied but yielded mixed results. While some showed metabolic benefits, none demonstrated robust effects on pain or mental health. The review’s lead author, Candy Wilson, Ph.D., APRN, emphasized:

“Our findings underscore a major imbalance in the evidence base: while diet, exercise, and supplements are frequently explored for metabolic outcomes, key issues like chronic pain and mental health—both critical to quality of life in PMOS—are largely overlooked.”

Pro Tip: If considering supplements, prioritize those with insulin-sensitizing properties (e.g., berberine, magnesium) or anti-inflammatory effects (e.g., curcumin), but consult a healthcare provider—especially during menopause, when drug interactions rise.

— ###

Future Trends: How PMOS Care Is Evolving

The FAU review isn’t just a critique—it’s a roadmap for the future. Experts predict several key shifts in PMOS management:

Future Trends: How PMOS Care Is Evolving
Polyendocrine Ovarian Syndrome

####

1. Integrated, Person-Centered Care Models

Traditional PMOS treatment often silos metabolic, hormonal, and psychological care. The next frontier? Holistic, lifespan approaches that:

  • Combine metabolic interventions (e.g., low-glycemic diets) with pain management (e.g., physical therapy, acupuncture).
  • Incorporate mental health screening as standard practice, given the high rates of depression, and anxiety.
  • Address sleep and stress, which exacerbate PMOS symptoms (e.g., cortisol dysregulation worsens insulin resistance).

Real-Life Example: The PCOS Awareness Association is piloting “PCOS Navigators” in primary care clinics—specialized nurses who track metabolic, pain, and mental health metrics across a woman’s lifespan.

####

2. Precision Medicine for Midlife PMOS

Genetic and epigenetic research is uncovering how PMOS manifests differently in women of varying ages. Future treatments may include:

Future Trends: How PMOS Care Is Evolving
Polyendocrine Ovarian Syndrome Exercise
  • Personalized nutrition: Gut microbiome testing to tailor probiotics or fiber-rich diets based on individual insulin responses.
  • Hormone-optimized therapies: Selective estrogen receptor modulators (SERMs) or bioidentical hormones to mitigate menopausal symptoms in PMOS patients.
  • AI-driven risk stratification: Algorithms predicting cardiometabolic risks in midlife, enabling early interventions.

Did you know? A 2025 study in Nature Reviews Endocrinology identified a genetic variant linked to severe PMOS in postmenopausal women, suggesting targeted therapies could emerge within the next decade.

####

3. Bridging the Research Gap: What’s Needed Now

The FAU review calls for:

  • More longitudinal studies tracking PMOS from reproductive to postmenopausal years.
  • Clinical trials focused on chronic pain and mental health interventions, such as:
  • Cognitive behavioral therapy (CBT) for PMOS-related anxiety.
  • Multimodal pain management (e.g., exercise + physical therapy + low-dose naltrexone for neuropathy).
  • Greater inclusion of diverse populations, as most PMOS research focuses on white women.

    • Reader Question: *“I’ve heard about ‘metabolic surgery’ for PMOS. Is this a viable option for midlife women?”*

    Answer: While bariatric surgery can improve metabolic markers in PMOS, its long-term safety in perimenopausal/menopausal women is not well studied. Current guidelines recommend it only for severe obesity with comorbidities—but lifestyle modifications (e.g., Mediterranean diet + strength training) should be exhausted first.

    — ###

    FAQ: Your Top Questions About PMOS in Midlife

    Q: Can menopause worsen PMOS symptoms?

    A: Yes. Declining estrogen during menopause can unmask or exacerbate PMOS-related insulin resistance, weight gain, and chronic pain. Some women report new-onset metabolic syndrome in their 40s–50s.

    Q: Are there supplements that help with both metabolism and pain?

    A: Limited evidence suggests turmeric (curcumin) and omega-3s may have mild anti-inflammatory effects, but results are inconsistent. For pain, magnesium glycinate and vitamin D (if deficient) are often recommended—but not as standalone solutions.

    Q: How can I advocate for better PMOS care?

    A:

    • Demand menopause-inclusive PMOS guidelines from your healthcare provider.
    • Push for integrated care models (e.g., endocrinologists + pain specialists + mental health therapists).
    • Support organizations like the PCOS Foundation or North American Menopause Society advocating for research.

    Q: Is there hope for reversing PMOS-related metabolic issues?

    A: While PMOS itself isn’t “curable,” lifestyle changes can significantly improve symptoms. A 2024 meta-analysis found that 12–18 months of consistent exercise and low-glycemic diets reduced insulin resistance by 30–50% in many women.

    — ###

    Your Next Steps: Taking Control of PMOS in Midlife

    PMOS is a lifelong condition, but its impact doesn’t have to define your health. Here’s how to stay ahead:

    • Prioritize movement: Strength training (2–3x/week) and walking (10K steps/day) are non-negotiable for metabolic and mental health.
    • Advocate for integrated care: Ask your provider about a team-based approach (e.g., dietitian + endocrinologist + physical therapist).
    • Track symptoms: Use apps like Flo or PCOS Dietitian to monitor metabolic, pain, and mood patterns.
    • Join the conversation: Share your experiences in our comments section—your insights could shape future research!

    Call to Action: PMOS in midlife is a growing health crisis—but it’s also an opportunity to redefine women’s healthcare. What’s one change you’ll make today to support your long-term health? Let us know in the comments, or explore our related articles on metabolic health and menopause.

    Subscribe to our newsletter for the latest research, expert interviews, and actionable tips on managing PMOS across the lifespan.

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    What Is Dry Needling? And Does It Work?

    by Chief Editor
    written by Chief Editor

    The Evolution of Pain Management: Moving Beyond the “Quick Fix”

    For years, dry needling was viewed as a niche tool in the physical therapy toolkit. Today, it has transitioned into a mainstream staple of orthopedic care, adopted by high-profile athletes like Caitlin Clark and Travis Kelce for recovery and maintenance.

    However, the industry is shifting. The conversation is moving away from using needles as a standalone “magic bullet” and toward integrating them into comprehensive recovery plans. Experts now emphasize that dry needling is most effective when paired with joint mobilization, therapeutic exercise, gait training, and soft tissue work.

    Did you know? While it looks like acupuncture, dry needling is fundamentally different. While acupuncture is based on traditional Chinese medicine and energy pathways, dry needling focuses strictly on musculoskeletal targets, such as myofascial trigger points.

    Expanding the Map: New Targets for Treatment

    While the practice began with a focus on muscle knots—those hyperirritable spots in taut bands of skeletal muscle—the scope of application is widening. Over the last decade, treatment has expanded to include tendons, fascia, scar tissue, and even bone surfaces.

    From Instagram — related to American, Association

    Emerging evidence also suggests a growing role for dry needling in treating headaches. This expansion indicates a trend toward treating the body’s connective tissues more holistically rather than focusing solely on isolated muscle spasms.

    To further enhance results, some practitioners are utilizing electro-stimulation. By running electricity through the needles, clinicians may be able to deliver faster pain relief, although research indicates these benefits remain primarily short-term.

    The Path Toward Standardization and Access

    One of the biggest hurdles for patients has been the “cash-pay” nature of the service. However, a significant shift in accessibility is underway. The American Chiropractic Association (ACA) and the American Physical Therapy Association (APTA) collaborated to apply for a specific CPT code for dry needling.

    This move toward a standardized code is designed to:

    • Enable more accurate descriptions of services by chiropractors and physical therapists.
    • Pave the way for better insurance coverage across the industry.
    • Allow the healthcare industry to collect better data on utilization and patient outcomes.

    While Medicare covers the treatment for lower back pain, many private insurers still do not, making the push for standardized coding a critical trend for patient access.

    Pro Tip: Since state laws vary wildly—with some states requiring 80 hours of education and others requiring only a “indicate of competency”—always ask your clinician about their specific certification, where they trained, and their years of experience.

    Balancing Innovation with Patient Safety

    As the popularity of dry needling grows, so does the scrutiny regarding safety. While the procedure is generally considered safe, the risk is not zero. Common side effects include bruising, bleeding, or temporary post-treatment pain.

    What Is Dry Needling?: Benefits And How Dry Needling Works

    Rare but serious complications, such as the collapsed lung experienced by Pittsburgh Steelers linebacker T.J. Watt, highlight the necessity of qualified practitioners. This has led to a growing push for stricter certification standards to prevent errors like forgotten needles or misplaced insertions.

    It is also becoming clearer who should avoid the treatment. Dry needling is not appropriate for individuals with:

    • Bleeding disorders or weakened immune systems.
    • Active skin infections or cancer.
    • Lymphedema (swelling) or pregnancy.

    Frequently Asked Questions

    Is dry needling the same as acupuncture?

    No. Acupuncture is based on traditional Chinese medicine and energy pathways. Dry needling focuses solely on musculoskeletal targets, like trigger points, to manage neuromusculoskeletal pain.

    Does dry needling provide long-term relief?

    Evidence for long-term benefits is currently low-quality. While many patients report immediate relief, increased strength, and better range of motion, some experts argue it is a short-term solution that may not address the root cause of the pain.

    Is the procedure safe?

    Yes, when practiced correctly, significant complications are rare (appearing in less than 0.1% of cases). However, risks like bruising or, in very rare instances, a collapsed lung exist.

    Who can legally perform dry needling?

    This depends on the state. In California, New York, and Hawaii, the procedure is restricted to licensed acupuncturists. In other states, it is performed by physical therapists and chiropractors.

    Want to optimize your recovery?

    Have you tried dry needling for chronic pain or athletic recovery? Share your experience in the comments below or subscribe to our newsletter for more deep dives into modern physical therapy!


    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    Drug-coated balloons reduce the need for permanent heart stents

    by Chief Editor
    written by Chief Editor

    The Shift Toward ‘Leave-Nothing-Behind’ Cardiology

    For decades, the gold standard for treating blocked arteries during a heart attack or unstable chest pain has been the drug-eluting stent (DES). These tiny metal mesh tubes are designed to keep arteries open permanently. However, a latest approach is gaining momentum: the “Leave-Nothing-Behind” strategy.

    This method utilizes sirolimus-eluting balloons (SEB), which are drug-coated balloons that deliver medication directly to the artery wall. Unlike stents, these balloons are removed after the procedure, leaving no permanent metal implant in the body.

    Did you recognize? Acute Coronary Syndrome (ACS) often leads to Non-ST-Elevation Myocardial Infarction (NSTEMI), which accounts for approximately 70% of all heart attacks.

    Understanding the Role of Drug-Coated Balloons

    In traditional percutaneous coronary intervention (PCI), or angioplasty, the permanent presence of metal in the artery can lead to complications. Research indicates an annual complication rate of 1% to 4% associated with these permanent implants.

    From Instagram — related to Leave, Nothing

    The SELUTION Drug Eluting Balloon (SEB) aims to mitigate these risks. By delivering the necessary medication without the permanent scaffold, clinicians can potentially avoid the long-term issues linked to metal stents while still restoring critical blood flow to the heart muscle.

    Comparing SEB and DES: What the Data Tells Us

    The effectiveness of this strategy has been put to the test in the SELUTION DeNovo study. A specific sub-study analyzed 1,089 patients suffering from NSTEMI or unstable angina to compare the outcomes of SEB (with provisional stenting) against traditional DES implantation over one year.

    The results suggest that the “Leave-Nothing-Behind” approach is a safe and effective alternative. The one-year data showed remarkably similar outcomes between the two groups:

    • Target Vessel Failure (TVF): 5.3% for SEB vs. 4.9% for DES.
    • Cardiac Death: 0.6% for SEB vs. 0.8% for DES.
    • Target-Vessel Related Myocardial Infarction (TV-MI): 3.1% for SEB vs. 2.8% for DES.
    • Clinically-Driven Target Vessel Revascularization (cd-TVR): 3.1% for SEB vs. 2.7% for DES.

    These figures indicate that for many patients, minimal stenting provides a level of safety and efficacy comparable to the traditional permanent stent approach.

    Pro Tip: For optimal results with SEB deployment, clinicians focus on precise balloon sizing and thorough lesion preparation to ensure the medication is delivered effectively to the artery wall.

    The Long-Term Impact on Artery Health

    Beyond the immediate statistics, the “Leave-Nothing-Behind” strategy offers a different philosophy regarding vascular health. By avoiding a permanent implant, the artery’s natural structure is better preserved.

    IN.PACT™ Admiral™ and IN.PACT™ 018 drug-coated balloons (DCB) Mechanism of Action

    According to Dr. Christian Spaulding, a professor of cardiology at Paris Descartes University, this approach provides clinicians with more flexibility for any future treatments the patient might require, as the artery remains free of permanent metal mesh.

    While the one-year data is promising, the medical community is now looking toward the future. Researchers note that the full potential benefits of minimal stenting will require longer-term observation, specifically focusing on five-year outcomes to determine the lasting impact on patient health.

    For more information on coronary interventions, you can explore the latest guidelines from the Society for Cardiovascular Angiography and Interventions or read our guide on modern cardiovascular trends.

    Frequently Asked Questions

    What is the difference between a DES and an SEB?

    A drug-eluting stent (DES) is a permanent metal mesh tube that stays in the artery to keep it open. A sirolimus-eluting balloon (SEB) is a temporary drug-coated balloon that delivers medication to the artery wall and is then removed.

    Who is the “Leave-Nothing-Behind” strategy for?

    This strategy is being evaluated for patients with Acute Coronary Syndrome (ACS), specifically those with Non-ST-Elevation Myocardial Infarction (NSTEMI) or unstable angina.

    Are there risks associated with permanent stents?

    Yes, studies have shown a 1% to 4% annual rate of complications due to the permanent presence of metal in the artery.

    Is the SEB strategy as effective as a stent?

    Recent sub-study data from the SELUTION DeNovo trial shows that at one year, rates of cardiac death and target vessel failure were low and similar between the SEB and DES groups.

    Join the Conversation: Do you think the future of heart health lies in minimizing permanent implants? Share your thoughts in the comments below or subscribe to our newsletter for the latest breakthroughs in medical technology.

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    Minimally invasive PTAB shows promise for patients with complex peripheral arterial disease

    by Chief Editor
    written by Chief Editor

    The Evolution of PAD Treatment: Moving Beyond Traditional Leg Bypass

    For millions of people living with peripheral arterial disease (PAD), the prospect of restoring blood flow to the legs has historically meant a difficult choice: minimally invasive endovascular therapies that may not be sufficient for complex blockages, or high-risk open surgical bypass surgery.

    However, a shift is occurring in the landscape of vascular care. The emergence of Percutaneous Transmural Arterial Bypass (PTAB) is redefining how clinicians approach long-segment superficial femoral artery (SFA) and popliteal artery occlusions, offering a middle ground that combines the logic of a surgical bypass with the recovery profile of a minimally invasive procedure.

    Did you know? PAD is a global health challenge impacting over 200 million people worldwide. Without effective treatment, reduced blood flow can lead to severe complications, including the risk of limb loss.

    Breaking the ‘Runoff’ Barrier in Complex PAD

    One of the most significant hurdles in treating advanced PAD has been “distal runoff”—the number of arteries that successfully carry blood to the lower leg, and foot. Traditionally, patients with single-vessel runoff (where only one of the three main arteries is functional) were viewed as high-risk, often leaving them with limited options other than open surgery.

    Recent data from the RODEO-PTAB substudy of the DETOUR2 trial has challenged this paradigm. By analyzing three-year data, researchers evaluated whether having only one runoff vessel predicted poorer outcomes after PTAB using the DETOUR System from Endologix LLC.

    The Data: Single-Vessel vs. Multi-Vessel Outcomes

    The findings suggest that the number of runoff vessels does not significantly hinder the success of PTAB. In a study of 191 evaluable patients, the results were strikingly similar across both groups:

    From Instagram — related to System, Bypass
    • Primary Patency: At three years, patency was 52.1% for single-vessel runoff compared to 59.5% for those with more than one vessel.
    • Target Lesion Revascularization (CD-TLR): Freedom from clinically-driven revascularization at three years was 65.1% for single-vessel runoff versus 67.2% for multi-vessel runoff.
    • Major Adverse Limb Events (MALE): The proportion of patients remaining MALE-free at three years was 59.9% for single-vessel runoff and 65.2% for multi-vessel runoff.

    These statistics indicate that PTAB can be a safe and effective alternative even for the most complex patients who were previously considered poor candidates for endovascular intervention.

    How the DETOUR System Redefines Revascularization

    Unlike traditional angioplasty or stenting, which attempt to clear a blocked artery, the DETOUR System creates an entirely new pathway for blood. By placing stents through the femoral vein, the system establishes a percutaneous, endovascular femoropopliteal bypass.

    This approach allows blood to bypass the diseased SFA segment entirely, improving circulation to the leg while avoiding the inpatient costs and periprocedural morbidity associated with open surgery. For patients experiencing debilitating leg pain, cramping, or numbness, this represents a significant leap in quality of life.

    “Findings from this study present that patients with single-vessel runoff maintained excellent patency through three years and can safely benefit from this minimally invasive treatment. These results give operators greater confidence to adopt this technology and treat complex patients who might otherwise be referred for open surgical bypass or have limited treatment options.”
    — Sameh Sayfo, MD, MBA, FSCAI, Interventional Cardiologist at Baylor Scott & White The Heart Hospital

    Pro Tip: If you or a loved one are discussing PAD treatment options, inquire your vascular specialist about “transmural bypass” options. Understanding whether your condition is categorized as TASC C or D can help determine if a minimally invasive bypass is a viable alternative to open surgery.

    Future Trends: The Next Frontier in Endovascular Care

    As PTAB becomes more integrated into standard care, the focus is shifting toward optimizing long-term success and expanding real-world application. Industry experts are looking toward several key areas of development:

    Real-World Evidence and Diverse Patient Profiles

    While clinical trials like DETOUR2 provide a controlled baseline, future trends point toward larger, real-world analyses. This will help clinicians understand how PTAB performs across broader, more diverse patient populations with varying comorbidities.

    Refining Anticoagulation Protocols

    A critical area of ongoing research is the post-procedure anticoagulation regimen. Researchers are currently evaluating whether specific medication protocols can further improve patency rates and reduce the demand for future revascularization.

    Reducing Surgical Dependency

    The long-term trend is a clear move toward “surgical avoidance.” By proving that complex patients—even those with limited distal runoff—can benefit from PTAB, the medical community is reducing the reliance on invasive open therapies, thereby lowering hospital stay durations and recovery times.

    Frequently Asked Questions

    What is PTAB?

    Percutaneous Transmural Arterial Bypass (PTAB) is a minimally invasive procedure that creates a new blood flow pathway to bypass blocked arteries in the leg, using a system of stents placed via the femoral vein.

    What is PTAB?
    System Bypass Percutaneous Transmural Arterial Bypass

    How does PTAB differ from a traditional surgical bypass?

    A traditional bypass requires open surgery to graft a vein or synthetic tube around a blockage. PTAB is endovascular, meaning it is performed through small incisions using catheters, which typically reduces recovery time and surgical risk.

    What does “single-vessel runoff” indicate?

    Runoff refers to the arteries that carry blood from the main leg arteries down into the foot. Single-vessel runoff means only one of the three primary arteries is open, which historically made the leg harder to treat via minimally invasive means.

    Is the DETOUR System available everywhere?

    The DETOUR System is currently approved for use within the United States.

    Aim for to stay updated on the latest breakthroughs in vascular health and medtech? Subscribe to our newsletter or leave a comment below to share your thoughts on the future of minimally invasive surgery.

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    Rising rotavirus cases highlight importance of childhood vaccination

    by Chief Editor
    written by Chief Editor

    The Evolution of Childhood Immunization Strategies

    The landscape of pediatric healthcare is shifting toward a more nuanced approach to vaccination. Recent updates from the Centers for Disease Control and Prevention (CDC) have transitioned the childhood vaccine schedule from a broad list to a categorized system. This shift reduces the number of recommended vaccines from 17 to 11, organizing them into three distinct tiers.

    The Evolution of Childhood Immunization Strategies
    Health Rotavirus Centers for Disease Control and Prevention

    These categories include universally recommended vaccines, those for children at high risk, and vaccines administered after shared clinical decision-making between parents and doctors. This trend suggests a future where immunization is more tailored to the specific risk profile of the child, ensuring that the most critical protections remain a priority while allowing for personalized medical discussions.

    Did you know? Before the rotavirus vaccine was introduced in 2006, nearly every child in the United States was infected with the virus at least once by their 5th birthday.

    Leveraging Real-Time Surveillance for Public Health

    One of the most significant trends in managing infectious disease surges is the integration of wastewater monitoring. Tools like the WastewaterSCAN dashboard allow health officials to track pathogens in real time, providing a critical early warning system before cases peak in clinics and emergency rooms.

    From Instagram — related to In New Jersey, Health

    In New Jersey, this technology has already highlighted a general resurgence of rotavirus across the state. By utilizing the CDC’s Wastewater Monitoring Program, providers can better anticipate surges and urge parents to ensure their children are up to date on vaccinations, moving from a reactive to a proactive healthcare model.

    The Impact of Preventative Care on Hospital Resources

    The data underscores the massive burden that preventable illnesses place on the healthcare system. Prior to the availability of the rotavirus vaccine, the CDC reported that the virus caused:

    • More than 400,000 doctor visits annually.
    • Over 200,000 emergency room visits each year.
    • Between 55,000 and 70,000 hospitalizations for children under five.

    Since the vaccine’s introduction, annual hospitalizations among young children have dropped by 40,000 to 50,000, demonstrating how targeted immunization trends directly reduce the strain on pediatric emergency departments.

    Pro Tip: Timing is everything with the rotavirus vaccine. It is crucial for infants to receive their first dose before 15 weeks of age and complete the full series before they turn 8 months old.

    Addressing the Vaccination Coverage Gap

    Despite the availability of life-saving vaccines, a trend of varying coverage rates persists. In New Jersey, rotavirus vaccination coverage has been recorded at 72%, which sits slightly below the national average of 74%.

    Several Rotavirus cases confirmed in children in Shelby County

    Closing this gap is a primary focus for pediatric experts. Because rotavirus causes severe gastroenteritis—inflammation of the stomach and intestines—the risks of remaining unvaccinated include severe watery diarrhea, vomiting, fever, and abdominal pain. In severe cases, these symptoms lead to dehydration and hospitalization.

    Experts from Hackensack Meridian Children’s Health emphasize that vaccination remains the most effective tool to prevent these complications and provide parents with peace of mind.

    Quick Guide: Rotavirus Vaccine Administration

    The vaccine is administered orally, which avoids the stress of needles for infants. Depending on the brand, the series consists of either two or three doses, starting when the baby is two months old.

    Frequently Asked Questions

    What are the primary symptoms of rotavirus?

    Rotavirus typically manifests as severe watery diarrhea, vomiting, fever, and abdominal pain, which can lead to dangerous dehydration.

    When should a child start the rotavirus vaccine series?

    The series starts when a baby is two months old. The first dose must be administered before 15 weeks of age, and the series must be completed by 8 months.

    How has the vaccine changed outcomes for children?

    The CDC estimates that the vaccine has reduced annual rotavirus hospitalizations among young children in the U.S. By 40,000 to 50,000 cases.

    Want to stay informed on the latest pediatric health trends? Share your thoughts in the comments below or subscribe to our newsletter for more expert insights on protecting your family’s health.

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    tudy identifies intersectional biases affecting care for sickle cell patients

    by Chief Editor
    written by Chief Editor

    Sickle Cell Disease and the Fight Against Intersectional Bias in Healthcare

    A poignant storyline in the first season of the show “The Pitt” – depicting a Black woman with sickle cell disease initially dismissed as drug-seeking in an emergency department – has sparked renewed attention to systemic biases within healthcare. This isn’t merely a fictional portrayal; experts confirm it reflects a harsh reality for many individuals living with sickle cell disease.

    Unpacking the Layers of Bias

    Recent research from the University of Chicago Medicine, published in JAMA Network Open, delves into the complex interplay of factors contributing to disparities in care. The study identifies that negative descriptors in clinician notes for sickle cell patients are closely linked to stigma surrounding opioid use, potentially overshadowing the impact of race or chronic pain alone.

    Monica Peek, MD, MPH, of UChicago Medicine, explains the challenge of pinpointing the source of discrimination. “Part of the issue for Black patients – and many marginalized groups – is that many in this population have multiple social identities that may be stigmatized… So when patients experience discrimination in healthcare, it is challenging to pinpoint what identity may be triggering the behavior.”

    The Data Behind the Disparities

    The UChicago Medicine study analyzed electronic health records of over 18,000 adults, examining nearly 40,000 clinician notes for negative descriptors like “aggressive,” “noncooperative,” and “noncompliant.” Findings revealed that patients with sickle cell disease had higher odds of these negative descriptors compared to Black patients and those with chronic pain. However, their odds were similar to patients with opioid use disorder, suggesting a strong connection between bias and opioid stigma.

    This builds on previous research showing Black patients are more than 2.5 times more likely to have negative descriptors in their medical records compared to white patients. Further studies have demonstrated that biased language in patient records can lead to decreased clinician empathy and inaccurate recall of critical health details.

    Beyond Stigma: The Reality of Pain Management

    A key issue highlighted by researchers is the misconception surrounding opioid use in sickle cell disease. While patients often require opioid medications to manage chronic pain, the vast majority do not have an opioid use disorder. “Whereas patients with sickle cell disease routinely use opioid medications to manage their chronic pain, the vast majority do not have an opioid use disorder,” notes Peek. “It is a testament to the strength of their character that they do their best to live full lives while managing debilitating pain.”

    Beyond Stigma: The Reality of Pain Management

    Austin Wesevich, MD, emphasizes the importance of trust in the patient-clinician relationship. “Clinicians cannot measure pain directly without asking the patient, so it’s a choice to believe patients when they share their pain levels… a patient with sickle cell disease who experiences daily pain and who happens to be Black and asking for opioid treatment deserves no less trust than any other patient.”

    Innovative Solutions: Anti-Bias Curriculum

    Recognizing the need for change, UChicago Medicine has developed an anti-bias curriculum designed to mitigate these issues. The program utilizes skills-based learning through roleplay, coupled with education on how biases negatively impact care quality. Early data suggests the intervention is effective, with other institutions already expressing interest in adopting the curriculum.

    Pro Tip: Healthcare organizations can proactively address bias by implementing similar training programs, promoting diversity within their staff, and fostering a culture of empathy and respect.

    Future Trends in Addressing Healthcare Disparities

    The focus on intersectional bias in sickle cell care signals a broader trend toward recognizing the complex factors influencing health outcomes. Expect to see increased use of natural language processing (NLP) and machine learning to identify and address bias in electronic health records. The development of standardized pain assessment tools and culturally sensitive communication strategies will be crucial.

    The success of the UChicago Medicine intervention highlights the potential of targeted educational programs. Future initiatives may incorporate virtual reality simulations to provide clinicians with immersive experiences that challenge their biases and promote empathy.

    FAQ

    Q: What is sickle cell disease?
    A: A genetic blood disorder that causes red blood cells to become sickle-shaped, leading to pain and other complications.

    Q: Why are patients with sickle cell disease often stigmatized?
    A: Stigma often stems from misconceptions about pain management and opioid use, as well as racial biases.

    Q: What can be done to address bias in healthcare?
    A: Implementing anti-bias training, promoting diversity, and fostering a culture of empathy are key steps.

    Q: What role does technology play in identifying bias?
    A: NLP and machine learning can analyze electronic health records to identify patterns of biased language.

    Did you know? Patients with sickle cell disease often experience chronic pain that significantly impacts their quality of life. Effective pain management is essential, but often hindered by bias and stigma.

    Learn more about sickle cell disease and ongoing research at the University of Chicago Medical Center.

    What are your thoughts on this issue? Share your experiences and insights in the comments below!

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    EV-RNAs show promise for IBD diagnosis and treatment

    by Chief Editor
    written by Chief Editor

    The Future of IBD Treatment: Harnessing the Power of EV-RNAs

    Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, affects millions worldwide and is projected to impact over 1% of the population in early-industrialized countries by 2045. A recent comprehensive review published in ExRNA, led by researchers at Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, highlights a revolutionary approach to managing this chronic condition: extracellular vesicle-associated RNAs (EV-RNAs).

    What are EV-RNAs and Why are They Essential?

    EV-RNAs are essentially tiny “biological packages” secreted by cells, containing RNA molecules – including microRNAs and long non-coding RNAs – that act as messengers between cells. These vesicles play a crucial role in regulating the intestinal environment, influencing inflammation, and impacting the gut microbiome. Researchers are discovering that these molecules aren’t just bystanders in IBD, but key regulators that can be targeted for both diagnosis and treatment.

    Non-Invasive Diagnosis: A Game Changer

    Currently, diagnosing IBD often requires invasive endoscopic examinations. EV-RNAs offer a potential solution with non-invasive biomarkers detectable in easily accessible fluids like plasma and even saliva. Studies cited in the ExRNA review demonstrate remarkably high accuracy – with area under the curve (AUC) values ranging from 0.95 to 0.97 – in distinguishing active IBD from remission using specific EV-RNA signatures, such as elevated levels of long non-coding RNA H19 in plasma EVs.

    Pro Tip: The ease of sample collection (saliva, blood) could dramatically improve patient compliance and enable more frequent monitoring of disease activity.

    EV-RNA-Based Therapies: Beyond Traditional Approaches

    Traditional IBD treatments, like anti-inflammatory drugs and biologics, often come with systemic side effects and can lead to drug resistance. EV-RNA-based therapies offer a more targeted approach. Several strategies are showing promise in preclinical models:

    • Mesenchymal Stem Cell-Derived EVs (MSC-EVs): These EVs carry immunomodulatory miRNAs that can suppress inflammation and promote intestinal barrier repair. They offer a safer alternative to whole-cell stem cell therapy, with a lower risk of immune rejection.
    • Dietary and Plant-Derived EVs: EVs extracted from sources like bovine colostrum, Coptis chinensis, Centella asiatica, and tea contain functional miRNAs that can survive digestion and directly target inflamed intestinal tissues. For example, EVs from Coptis chinensis can restore zinc homeostasis in immune cells, reducing intestinal damage.
    • Engineered EVs: Researchers are modifying EVs to deliver therapeutic RNAs directly to inflamed tissues, offering personalized treatment options for patients who don’t respond to conventional therapies.

    Systemic Impact: Addressing Extraintestinal Complications

    IBD isn’t limited to the gastrointestinal tract. It’s often associated with complications affecting the liver and heart. The research highlights that EV-RNAs secreted by inflamed intestinal tissues can travel through the bloodstream and influence inflammatory responses in distant organs, providing a molecular link to these systemic issues.

    Systemic Impact: Addressing Extraintestinal Complications

    Did you know? Understanding the systemic role of gut-derived EV-RNAs could lead to therapies that prevent or mitigate these extraintestinal complications.

    Challenges and Future Directions

    Despite the exciting potential, several challenges remain. Standardized protocols for EV isolation, purification, and RNA detection are crucial to ensure consistent results across laboratories. Large-scale clinical trials are needed to validate the efficacy of EV-RNA-based diagnostics and therapies in human patients, and clear regulatory pathways for these novel treatments must be established.

    Frequently Asked Questions (FAQ)

    Q: What is the difference between Crohn’s disease and ulcerative colitis?
    A: Crohn’s disease can affect any part of the digestive tract with transmural inflammation, although ulcerative colitis is limited to the colorectal mucosa with superficial inflammation.

    Q: Are EV-RNA therapies currently available for IBD patients?
    A: No, EV-RNA therapies are still in the preclinical and early clinical stages of development. More research and clinical trials are needed before they become widely available.

    Q: How can I learn more about EV-RNA research?
    A: You can explore the research published in the journal ExRNA and follow updates from leading research institutions like Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine.

    The field of EV-RNA research is rapidly evolving, offering a beacon of hope for the millions affected by IBD. As research progresses and challenges are addressed, these tiny vesicles could revolutionize the way we diagnose, monitor, and treat this debilitating disease.

    Want to stay informed about the latest advancements in IBD research? Subscribe to our newsletter for updates and insights from leading experts.

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    TENS Pulses Defeat Fibromyalgia Pain and Fatigue

    by Chief Editor
    written by Chief Editor

    TENS Therapy: A Fresh Wave of Relief for Chronic Pain and Fatigue?

    For millions grappling with fibromyalgia and, increasingly, long-COVID symptoms, a glimmer of hope is emerging. A recent clinical trial led by the University of Iowa has demonstrated the significant benefits of combining Transcutaneous Electrical Nerve Stimulation (TENS) with physical therapy, offering a drug-free approach to reducing both movement-evoked pain and debilitating fatigue.

    The Fibromyalgia & Long-COVID Connection

    Fibromyalgia, affecting an estimated 4-7% of the population, is characterized by widespread musculoskeletal pain accompanied by fatigue, sleep disturbances, and cognitive difficulties. Interestingly, a growing number of individuals experiencing long-COVID are reporting fibromyalgia-like symptoms, prompting researchers to explore existing treatments for potential crossover benefits. A pilot study highlighted in Scientific Reports investigated TENS for fibromyalgia-like syndrome in long-COVID patients, suggesting a potential shared pathway for pain management.

    How TENS Works: Beyond Just Blocking Pain

    TENS utilizes a small, portable device that delivers mild electrical pulses through the skin via adhesive electrodes. Traditionally used for pain management, the recent research suggests a more nuanced effect. The therapy isn’t simply masking pain signals; it appears to influence the nervous system in a way that reduces the overall “alert level” associated with chronic pain, thereby alleviating fatigue. This is particularly significant as effective treatments for fatigue remain limited.

    Real-World Results: The FM-TIPS Trial

    The groundbreaking study, known as FM-TIPS, involved 384 participants across 28 outpatient physical therapy clinics in the Midwest. This “real-world” setting is crucial, as it reflects the complexities of treating patients outside of a controlled laboratory environment. Participants using TENS in conjunction with physical therapy experienced a significant reduction in movement-evoked pain, and importantly, a noticeable decrease in fatigue levels. Remarkably, the benefits persisted for at least six months.

    Key Findings & The 80% Rule

    The FM-TIPS trial revealed several compelling statistics: 80% of participants found TENS helpful, and 70% reported an overall improvement in their condition. Unlike many pain medications that require escalating doses to maintain effectiveness, TENS maintained its benefits over time. The study similarly demonstrated a “dose-dependent” effect – consistent, daily use (around two hours) yielded the most substantial improvements.

    Beyond Pain: Community Engagement & Trial Success

    The success of the FM-TIPS trial wasn’t solely due to the treatment itself. Researchers emphasized the importance of community engagement in recruitment, and enrollment. Strategies to connect with patients in real-world settings, particularly in rural areas (nearly 50% of participants were from rural communities), were vital to the study’s broad representation and validity.

    The Future of TENS: Personalized Approaches & Integration with Digital Health

    Even as the FM-TIPS trial provides strong evidence for the efficacy of TENS, the future of this therapy likely lies in personalized approaches. Researchers are exploring ways to optimize TENS parameters – frequency, intensity, electrode placement – based on individual patient characteristics and pain profiles. Integration with digital health technologies, such as wearable sensors and mobile apps, could allow for remote monitoring of treatment adherence and real-time adjustments to TENS settings.

    Another potential avenue for exploration is combining TENS with other non-pharmacological interventions, such as mindfulness-based stress reduction and cognitive behavioral therapy. A holistic approach that addresses both the physical and psychological aspects of chronic pain and fatigue is likely to yield the most sustainable results.

    FAQ: TENS Therapy – Common Questions Answered

    Q: Can I just buy a TENS unit and skip physical therapy?

    A: No. The study clearly indicates that TENS is most effective when used in addition to physical therapy and other existing treatments. It enhances the benefits of PT, allowing for greater participation in exercise and daily activities.

    Q: Will the “zaps” stop working if I use it every day?

    A: Surprisingly, no. The study showed a dose-dependent response, meaning consistent daily use for 60 days led to the best outcomes, and the relief continued for at least six months.

    Q: Is TENS therapy safe?

    A: The study reported no serious adverse events. Minor side effects, such as skin irritation, were reported by a small percentage of participants.

    Pro Tip: Talk to your physical therapist about whether TENS therapy is right for you. They can assess your condition and develop a personalized treatment plan.

    Have you tried TENS therapy for chronic pain or fatigue? Share your experience in the comments below!

    0 comments
    0 FacebookTwitterPinterestEmail
    Tech

    The molecular mechanism that turns cool temps into nerve signals

    by Chief Editor
    written by Chief Editor

    Unlocking the Secrets of Cold: How New Discoveries Could Revolutionize Pain Treatment

    The sensation of cold, from the bracing chill of an ice cube to the soothing coolness of menthol, has long been a scientific puzzle. Now, researchers at UC San Francisco have made a breakthrough in understanding how our bodies detect temperature, specifically focusing on a protein called TRPM8. This discovery, published in Nature on March 25th, 2026, not only explains a fundamental aspect of human physiology but also opens doors for novel pain therapies.

    The TRPM8 Channel: A Gatekeeper of Cold Sensation

    TRPM8, found in nerve cells, acts like a tiny gate, opening to signal the brain when temperatures drop. For years, scientists have known TRPM8’s role in sensing cold and the cooling effect of menthol, but its precise mechanism remained elusive. The challenge lay in visualizing the protein’s dynamic changes as it responded to temperature fluctuations. Traditional structural biology often focuses on capturing proteins in stable states, missing crucial information about their movement.

    “Everyone always wants to understand how temperature sensing works, but it turns out to be a very technically challenging question to answer. So, to finally have insight into This represents really very exciting,” stated a researcher involved in the study.

    A New Approach to Protein Imaging

    The UCSF team overcame this hurdle by imaging TRPM8 while it remained embedded in cell membranes. This approach proved critical, as isolating the protein caused it to fall apart. They employed two powerful techniques: cryo-electron microscopy (cryo-EM) for static snapshots and hydrogen-deuterium exchange mass spectrometry (HDX-MS) to track the protein’s movements in real-time.

    “Just as looking at a photo of a horse can’t tell you how prompt it runs, the electron microscopy alone can’t tell us how the molecule moves and what drives those movements,” explained a co-first author of the study. “But combining these two techniques gave us a window into what was happening.”

    How Cold Activates TRPM8: A Molecular Dance

    The analysis revealed that cold stabilizes a specific region of the TRPM8 channel, triggering a helix to move. This movement allows a lipid molecule to slide into place, locking the channel open and sustaining the cold signal. Comparing human TRPM8 to its avian counterpart – which is less sensitive to cold but responds to menthol – helped pinpoint the features responsible for cold detection.

    Implications for Pain Management and Beyond

    This research has significant implications for treating conditions like cold allodynia, where even mild cold triggers severe pain. Several compounds that block TRPM8 are currently in clinical trials and understanding the protein’s structure could lead to more targeted and effective therapies. Researchers are now applying this same strategy to study TRPV1, the heat-sensing channel discovered by Nobel laureate Julius in 1997.

    The Future of Structural Biology: Capturing Movement

    The success of this study highlights a shift in structural biology, emphasizing the importance of understanding protein dynamics. “The lessons we learned in studying this channel are actually very broadly useful,” noted a researcher. “Dynamic behavior is critical for the function of many proteins, and you can’t understand dynamic behavior from one snapshot of a protein’s structure.”

    Did you know? The researcher who led this study also won the 2021 Nobel Prize in Physiology or Medicine for his earlier work on the heat-sensing protein TRPV1.

    Frequently Asked Questions

    Q: What is TRPM8?
    A: TRPM8 is a protein in nerve cells that acts as a sensor for cold temperatures and the cooling sensation of menthol.

    Q: Why was it difficult to study TRPM8?
    A: TRPM8 is unstable when isolated from cells and traditional imaging methods require stable protein structures.

    Q: How did researchers overcome these challenges?
    A: They imaged TRPM8 while it was still embedded in cell membranes, using cryo-EM and HDX-MS.

    Q: What are the potential applications of this research?
    A: It could lead to new treatments for pain conditions like cold allodynia.

    Pro Tip: Maintaining optimal body temperature is crucial for overall health. Dress appropriately for the weather and stay hydrated to support your body’s natural temperature regulation mechanisms.

    Aim for to learn more about the fascinating world of sensory biology? Explore our other articles on neuroscience and pain management.

    0 comments
    0 FacebookTwitterPinterestEmail
    Health

    New insights into acupoint sensitization in disease diagnosis and therapy

    by Chief Editor
    written by Chief Editor

    The Dynamic World of Acupoints: A New Era for Acupuncture and Beyond

    For centuries, acupuncture has relied on the precise location of acupoints to restore health. But what if these points aren’t fixed locations, but rather dynamic interfaces that change with the body’s condition? Emerging research suggests this is precisely the case, opening up exciting new avenues for understanding and applying this ancient practice.

    From Static Landmarks to Biological Interfaces

    Traditional acupuncture theory centers on specific acupoints along energy pathways, or meridians. But, the biological basis of these points has long been debated. Recent studies, particularly those from the Institute of Acupuncture and Moxibustion at the China Academy of Chinese Medical Sciences, are revealing that acupoints are not static. Instead, they are “sensitized” by underlying visceral diseases, becoming more responsive to stimulation.

    This sensitization arises from complex connections between internal organs and the body surface, known as somato-visceral neural anatomy. When an organ experiences pathology, it activates shared spinal segments with corresponding body regions, leading to neurogenic inflammation. This inflammation manifests as localized changes – tenderness, temperature fluctuations, or altered pain thresholds – effectively transforming the acupoint into a diagnostic indicator.

    The Science Behind Sensitized Acupoints

    Researchers have identified several key mechanisms driving acupoint sensitization. These include peripheral and central sensitization pathways involving dorsal root ganglia, sympathetic-sensory coupling, and spinal dorsal horn neuronal sensitization. Advanced techniques like in vivo calcium imaging demonstrate that visceral inflammation amplifies neural responsiveness in corresponding somatic regions.

    Large-scale clinical investigations, involving over 12,000 patients, have consistently linked specific diseases – coronary heart disease, functional gastrointestinal disorders, and pulmonary dysfunction – to predictable patterns of sensitized acupoints. Importantly, stimulating these sensitized points produces stronger biological effects than stimulating non-sensitized sites, enhancing autonomic activities and improving organ function.

    Implications for Clinical Practice and Research

    The concept of acupoint sensitization doesn’t negate traditional point selection rules. Rather, it refines clinical decision-making by identifying sites where therapeutic signals are biologically amplified. Selecting tender or reactive points, a long-standing practice in acupuncture, now has a clear scientific rationale.

    This understanding has significant implications for clinical research. Incorporating sensitization status into study design could help distinguish true therapeutic effects from placebo responses, addressing a common criticism of acupuncture. Identifying sensitized acupoints could enhance treatment precision and efficacy across a range of visceral disorders.

    Beyond Acupuncture: A Broader Neuroscience Perspective

    The implications extend beyond acupuncture itself. This framework contributes to broader neuroscience by illustrating how internal disease states reshape sensory processing and autonomic regulation. Recognizing acupoints as dynamic structures may help bridge traditional medical practices with modern systems biology, and neurophysiology.

    Did you know? Sensitized acupoints symbolize the body’s self-regulatory instinct, where even minor external stimulation can elicit disproportionately large physiological effects.

    Future Trends: Personalized Acupuncture and Diagnostic Tools

    Several exciting trends are emerging as a result of this research:

    • Personalized Acupuncture: Tailoring treatment plans based on individual sensitization profiles, rather than relying solely on standardized point locations.
    • Diagnostic Applications: Utilizing acupoint sensitivity as a non-invasive diagnostic tool to identify early signs of visceral dysfunction.
    • Integration with Imaging Technologies: Combining acupuncture with advanced imaging techniques to visualize and quantify acupoint sensitization in real-time.
    • Development of Novel Stimulation Techniques: Exploring new methods to target and modulate sensitized acupoints, potentially enhancing therapeutic outcomes.

    FAQ

    Q: Does this mean traditional acupuncture point locations are wrong?
    A: Not at all. It means acupoints are more dynamic than previously thought. Sensitization adds another layer of understanding to their function.

    Q: Can anyone measure acupoint sensitization?
    A: Currently, it’s primarily assessed through clinical examination – identifying tenderness or other changes at specific points. Research is ongoing to develop more objective measurement tools.

    Q: Is acupoint sensitization the same as a trigger point?
    A: While both involve localized tenderness, acupoint sensitization is specifically linked to underlying visceral disease, whereas trigger points are often associated with musculoskeletal issues.

    Pro Tip: When seeking acupuncture treatment, look for a practitioner who considers individual sensitivity and responsiveness when selecting points.

    Want to learn more about the fascinating intersection of traditional medicine and modern science? Explore our other articles on integrative health and pain management.

    Share your thoughts! Have you experienced the benefits of acupuncture? Leave a comment below.

    0 comments
    0 FacebookTwitterPinterestEmail
    Newer Posts
    Older Posts